ALS therapy grants reauthorization

Full Title:
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Summary#

This bill reauthorizes and updates the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. It makes small program changes to how grants are reviewed, asks drug developers to share interim trial data, clarifies what counts as a phase 3 trial, and requires new FDA and GAO reports about ALS and similar diseases. The broad goal is to speed development and regulatory attention for ALS and other rare neurodegenerative diseases.

  • Main change: extends existing authorities and grant eligibility dates from 2026 to 2031.
  • Grant review: when deciding on renewals, the FDA must assess clinical trial enrollment and must request interim clinical trial data from manufacturers.
  • Definition change: “phase 3” trials now includes phase 2/3 combined trials and planned phase 3 trials not yet enrolling.
  • FDA report: FDA must publish an updated 5-year action plan and a review of its 2022 Action Plan within one year.
  • GAO report: shifts the timing of the Government Accountability Office review to 5 years after enactment and asks GAO to cover the 10-year period starting at enactment.

What it means for you#

  • Patients and families: The bill aims to speed work on ALS treatments. This could mean faster attention to promising drugs, but it does not guarantee faster approvals or new treatments.
  • Researchers and grant recipients: Grant eligibility and program authority continue through 2031. Grant renewals may be judged partly on trial enrollment status and interim trial data shared by manufacturers.
  • Drug developers / manufacturers: The FDA will request interim clinical trial data when grants are renewed for related investigational drugs. The bill does not say the manufacturer must comply, only that FDA must request the data.
  • Rare neurodegenerative disease communities (beyond ALS): The FDA must describe how it will include non-ALS rare neurodegenerative diseases in its action plan and report on how the 2022 Action Plan affected those diseases.
  • Food and Drug Administration (FDA): Must publish an updated 5-year action plan with resource estimates and coordination approaches within one year. Must assess trial enrollment and request interim data when reviewing certain grant renewals.
  • Government Accountability Office (GAO): Must prepare a review 5 years after enactment that looks at the first 10 years starting at enactment.

Expenses#

No publicly available information.

  • The bill extends the period during which grants for ALS research may be awarded through FY2031. No dollar amounts or appropriations are included in the text provided.
  • The FDA will likely need staff time and resources to prepare the required 5-year action plan, to assess trial enrollment for grant renewals, and to request and review interim trial data.
  • Manufacturers may incur costs to prepare and share interim clinical trial data if they choose to comply.
  • The GAO will incur costs to prepare the broader 10-year review; the text changes the timing but does not list funding.

Proponents' View#

  • The bill appears intended to keep the ALS grant and program authorities active through 2031 so work on therapies can continue.
  • It aims to make grant decisions better informed by clinical trial progress by having the FDA check trial enrollment and request interim data.
  • Clarifying that combined phase 2/3 and planned phase 3 trials count as phase 3 could speed consideration of therapies that are already moving toward later-stage testing.
  • Requiring an updated FDA action plan with resource estimates could improve planning and coordination with communities affected by rare neurodegenerative diseases.
  • Extending and broadening GAO review timing could allow a longer-term look at program results.

Opponents' View#

  • One concern is that the bill only requires the FDA to request interim clinical trial data, not to require manufacturers to provide it. This may limit the rule’s practical effect.
  • The bill asks the FDA to identify resources needed to carry out the plan but does not provide funding. It is unclear whether the FDA will get the money or staff it needs.
  • Requiring more reporting and reviews may increase administrative work for the FDA and GAO without clear funding or timelines for follow-up action.
  • Clarifying “phase 3” to include planned trials not yet enrolling could raise questions about how close a program must be to actual enrollment to count as late-stage. The bill does not define standards for that decision.
  • It is unclear how FDA will use interim data in grant decisions or what protections will apply to sensitive or proprietary information shared by manufacturers.